Merck's Personalized Cancer Vaccine Shows Success in Late-Stage Melanoma Trial
On August 19, Merck (MRK) announced that its personalized cancer vaccine, developed with Moderna (MRNA), successfully met key endpoints in a Phase 3 trial for melanoma. The treatment, called Intismeran, was tested alongside Keytruda and showed improved recurrence-free survival and distant metastasis-free survival compared to Keytruda alone. The positive results led to an immediate market reaction: Merck's stock surged by about 12.5%, adding $43 billion in value within a single day. Analysts noted that while the melanoma program is projected for peak annual sales of around $4.3 billion, investors were likely pricing in broader potential across other cancers. The vaccine also addresses Merck's looming patent expiration issue on Keytruda by 2028. As its top-selling drug faces generic competition, Intismeran offers a durable revenue stream due to the difficulty of replicating personalized mRNA therapies.
Topics: cancer vaccine melanoma treatment Merck & Moderna partnership Phase 3 trial success